Progress with retroviral gene vectors

Palù, Giorgio; Parolin, Cristina; Takeuchi, Yasuhiro; Pizzato, Massimo

doi:10.1002/(sici)1099-1654(200005/06)10:3<185::aid-rmv285>3.0.co;2-8

Cited by 76 publications

(39 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, not all virus/glycoprotein pairs are able to complement one another. HIV-1 is compatible with glycoproteins from many families of viruses, including rhabdoviruses, other retroviruses, and filoviruses, but the compatibility does not strictly follow family lines (14,17,29). For instance, HIV-1 is compatible with the Env glycoprotein from the gammaretrovirus Friend murine leukemia virus (F-MLV), but it is not compatible with the Env glycoprotein from gibbon ape leukemia virus (GaLV), even though F-MLV and GaLV belong to the same genus (6,21,24,39).…”

mentioning

confidence: 99%

Sequences in Gibbon Ape Leukemia Virus Envelope That Confer Sensitivity to HIV-1 Accessory Protein Vpu

Janaka

Lucas

Johnson

2011

J Virol

View full text Add to dashboard Cite

HIV-1 efficiently forms pseudotyped particles with many gammaretrovirus glycoproteins, such as Friend murine leukemia virus (F-MLV) Env, but not with the related gibbon ape leukemia virus (GaLV) Env or with a chimeric F-MLV Env with a GaLV cytoplasmic tail domain (CTD). This incompatibility is modulated by the HIV-1 accessory protein Vpu. Because the GaLV Env CTD does not resemble tetherin or CD4, the well-studied targets of Vpu, we sought to characterize the modular sequence in the GaLV Env CTD required for this restriction in the presence of Vpu. Using a systematic mutagenesis scan, we determined that the motif that makes GaLV Env sensitive to Vpu is INxxIxxVKxxVxRxK. This region in the CTD of GaLV Env is predicted to form a helix. Mutations in the CTD that would break this helix abolish sensitivity to Vpu. Although many of these positions can be replaced with amino acids with similar biophysical properties without disrupting the Vpu sensitivity, the final lysine residue is required. This Vpu sensitivity sequence appears to be modular, as the unrelated Rous sarcoma virus (RSV) Env can be made Vpu sensitive by replacing its CTD with the GaLV Env CTD. In addition, F-MLV Env can be made Vpu sensitive by mutating two amino acids in its cytoplasmic tail to make it resemble more closely the Vpu sensitivity motif. Surprisingly, the core components of this Vpu sensitivity sequence are also present in the host surface protein CD4, which is also targeted by Vpu through its CTD.

show abstract

mentioning

confidence: 99%

Sequences in Gibbon Ape Leukemia Virus Envelope That Confer Sensitivity to HIV-1 Accessory Protein Vpu

Janaka

Lucas

Johnson

2011

J Virol

View full text Add to dashboard Cite

show abstract

“…Other features, like coding capacity, infectivity, and promoters for expression of such vector systems, have been subjects of several reviews (for instance, Refs. [63,93,94]) and can help determine which is best to utilize. Nonetheless, even potential limitations of a particular system can be overcome.…”

Section: Vector Technology and Usementioning

confidence: 99%

Controlled and localized genetic manipulation in the brain

Aronoff

Petersen

2006

Journal of Cellular and Molecular Medicine

View full text Add to dashboard Cite

Establishing the contributions of inherited genes relative to experience in brain function forms a central theme of neuroscience. There is little doubt that both activity-dependent neuronal plasticity and genetically determined programs generate important influences on the developing and the adult nervous system. The ability to change behaviour in response to new environmental hazards and AbstractBrain structure and function are determined in part through experience and in part through our inherited genes. A powerful approach for unravelling the balance between activity-dependent neuronal plasticity and genetic programs is to directly manipulate the genome. Such molecular genetic studies have been greatly aided by the remarkable progress of large-scale genome sequencing efforts. Sophisticated mouse genetic manipulations allow targeted point-mutations, deletions and additions to the mouse genome. These can be regulated through inducible promoters expressing in genetically specified neuronal cell types. However, despite significant progress it remains difficult to target specific brain regions through transgenesis alone. Recent work suggests that transduction vectors, like lentiviruses and adeno-associated viruses, may provide suitable additional tools for localized and controlled genetic manipulation. Furthermore, studies with such vectors may aid the development of human genetic therapies for brain diseases.

show abstract

“…Intracellular expression of a therapeutic gene can prevent de novo viral infection, suppress viral replication in infected cells or endow the cells with novel properties that may play an adjuvant role in inhibiting HIV infection/replication. Since the vectors, the gene products and the strategies that can be deployed for GT of AIDS have been the subject of recent reviews, [14][15][16] we focus here on the therapeutic use of genetically treated cells and propose a new combined modality of gene and cell therapy. This is based on the adoptive transfer of HIV-genetically resistant CD4 cells that recognize specific antigens of opportunistic pathogens or of HIV itself.…”

Section: Introductionmentioning

confidence: 99%

Genetically modified immunocompetent cells in HIV infection

Palù

Pira²,

Gennari

et al. 2001

Gene Ther

View full text Add to dashboard Cite

Even in the era of highly active antiretroviral therapy (HAART), gene therapy (GT) can remain a promising approach for suppressing HIV infection, especially if complemented with other forms of pharmacological and immunological intervention. A large number of vectors and targets have been studied. Here we discuss the potential of genetically treated, antigen-specific immunocompetent cells for adoptive autologous immunotherapy of HIV infection. Cellu-

show abstract

Progress with retroviral gene vectors

Cited by 76 publications

References 123 publications

Sequences in Gibbon Ape Leukemia Virus Envelope That Confer Sensitivity to HIV-1 Accessory Protein Vpu

Sequences in Gibbon Ape Leukemia Virus Envelope That Confer Sensitivity to HIV-1 Accessory Protein Vpu

Controlled and localized genetic manipulation in the brain

Genetically modified immunocompetent cells in HIV infection

Contact Info

Product

Resources

About